Goldman Sachs
NAUT icon

Goldman Sachs’s Nautilus Biotechnolgy NAUT Stock Holding History

Goldman Sachs’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$473K Sell
252,751
-138,017
-35% -$364K ﹤0.01% 5732
2026
Q1 		$1.52M Buy
390,768
+93,331
+31% +$229K ﹤0.01% 4771
2025
Q4 		$580K Buy
297,437
+179,721
+153% +$295K ﹤0.01% 5501
2025
Q3 		$99.5K Sell
117,716
-197,222
-63% -$145K ﹤0.01% 6078
2025
Q2 		$228K Buy
314,938
+143,151
+83% +$108K ﹤0.01% 5595
2025
Q1 		$148K Sell
171,787
-23,908
-12% -$35.5K ﹤0.01% 5706
2024
Q4 		$329K Buy
195,695
+33,367
+21% +$79.8K ﹤0.01% 5460
2024
Q3 		$463K Buy
162,328
+79,439
+96% +$206K ﹤0.01% 5091
2024
Q2 		$194K Buy
82,889
+19,853
+31% +$51.8K ﹤0.01% 5278
2024
Q1 		$185K Sell
63,036
-3,985
-6% -$11.3K ﹤0.01% 5133
2023
Q4 		$200K Sell
67,021
-13,665
-17% -$39.1K ﹤0.01% 5153
2023
Q3 		$255K Sell
80,686
-14,475
-15% -$47.1K ﹤0.01% 4960
2023
Q2 		$368K Buy
95,161
+3,396
+4% +$9.78K ﹤0.01% 4903
2023
Q1 		$254K Buy
91,765
+20,950
+30% +$43.9K ﹤0.01% 5191
2022
Q4 		$127K Sell
70,815
-3,752
-5% -$7.24K ﹤0.01% 5423
2022
Q3 		$158K Sell
74,567
-3,236
-4% -$8.14K ﹤0.01% 5559
2022
Q2 		$209K Sell
77,803
-15,761
-17% -$58.7K ﹤0.01% 5619
2022
Q1 		$406K Buy
93,564
+35,888
+62% +$147K ﹤0.01% 5467
2021
Q4 		$299K Buy
57,676
+47,253
+453% +$253K ﹤0.01% 5671
2021
Q3 		$64K Buy
+10,423
New +$83.1K ﹤0.01% 5996
2021
Q1 		– Sell
-122,500
Closed -$1.33M – 6249
2020
Q4 		$1.33M Buy
+122,500
New +$1.29M ﹤0.01% 4014

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Goldman Sachs's NAUT Position: Q2 2026 in Review

Goldman Sachs reduced its Nautilus Biotechnolgy (NAUT) stake by 35% in Q2 2026, selling an estimated $364K and leaving 252,751 shares worth $473K. The position accounts for ﹤0.01% of the portfolio, ranked #5732.

Goldman Sachs first reported a position in NAUT in Q4 2020 and has held it in 21 quarters since. The position peaked at $1.52M in Q1 2026. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

  • Goldman Sachs held 252,751 shares of Nautilus Biotechnolgy worth $473K as of Q2 2026.
  • Goldman Sachs sold 138,017 Nautilus Biotechnolgy shares in Q2 2026, an estimated $364K.
  • Nautilus Biotechnolgy made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5732 holding.
  • Goldman Sachs first reported a position in Nautilus Biotechnolgy in Q4 2020 and has held it in 21 quarters since.
  • Goldman Sachs's Nautilus Biotechnolgy position peaked at $1.52M in Q1 2026.
  • 93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.